Product Program year 2025 Source: CMS Open Payments

Clinical Trial Product

Device Clinical Trial Product_IC

Open in the dashboard

General payments

$323,732

272 payments

Research payments

$18,191,776

4,951 payments

Through program year 2025, $323,732 in general payments and $18,191,776 in research payments were reported against Clinical Trial Product (Clinical Trial Product_IC).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

4 rows
Year Kind Amount Payments
2025 General $321,261 230
2025 Research $7,092,048 2,357
2024 Research $11,099,728 2,594
2022 General $2,471 42

Breakdown

Who paid General payments · program years 2022–2025
  1. Boston Scientific Corporation $323,732 272 payments
Top recipients General payments · program year 2025
  1. Paul Underwood Cardiovascular Disease · Scottsdale, AZ $122,625 38% · 10 payments
  2. Alejandro Rabinstein Neurology · Rochester, MN $28,125 9% · 25 payments
  3. Robert Taylor Neurological Surgery · Oxnard, CA $26,950 8% · 27 payments
  4. Michael Manoles Interventional Cardiology · Minneapolis, MN $24,275 8% · 22 payments
  5. John Schoenhard Clinical Cardiac Electrophysiology · St Cloud, MN $22,800 7% · 21 payments

The top 5 of 48 recipients; each share is of general payments naming this product in 2025.

The top 25 recipients, free in the app

Specialties paid General payments · program year 2025
  1. Cardiovascular Disease Internal Medicine $163,411 51% · 10 practitioners
  2. Interventional Cardiology Internal Medicine $55,805 17% · 22 practitioners
  3. Neurology Psychiatry & Neurology $30,000 9% · 2 practitioners
  4. Neurological Surgery $26,950 8% · 1 practitioner
  5. Clinical Cardiac Electrophysiology Internal Medicine $22,865 7% · 2 practitioners

The top 5 of 11 specialties; each share is of general payments naming this product to practitioners with a specialty in 2025. Each practitioner is counted under their primary specialty.

The top 25 specialties, free in the app

Where the money went General payments · program year 2025
  1. Arizona $122,625 38% · 1 recipient
  2. Minnesota $80,530 25% · 6 recipients
  3. Massachusetts $53,340 17% · 7 recipients
  4. California $28,578 9% · 5 recipients
  5. New York $12,166 4% · 12 recipients

The top 5 of 17 states; each share is of general payments naming this product in 2025 where a state was reported.

The top 25 states, free in the app

272 general · 4,951 research

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record